Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. MDPCP - Wikipedia
MDPCP - Wikipedia
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
MDPCP
Identifiers
CAS Number
  • 3034185-93-5 checkY
PubChem CID
  • 165360308  
ChemSpider
  • 129539440
Chemical and physical data
FormulaC18H25NO2
Molar mass287.403 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • C1CCC(CC1)(N1CCCCC1)c1ccc2c(c1)OCO2
InChI
  • InChI=1S/C18H25NO2/c1-3-9-18(10-4-1,19-11-5-2-6-12-19)15-7-8-16-17(13-15)21-14-20-16/h7-8,13H,1-6,9-12,14H2
  • Key:ANUGFLCSICVCSB-UHFFFAOYSA-N

Methylenedioxyphencyclidine (3',4'-MD-PCP, MDPCP) is a recreational designer drug with dissociative effects. It is an arylcyclohexylamine derivative, with similar effects to related drugs such as 3-MeO-PCP and 4-MeO-PCP.[1][2]

Chemical properties

[edit]

MDPCP has the molecular formula C18H25NO2 and a molar mass of 287.403 g·mol−1. Its structural characteristics include a methylenedioxy functional group attached to the phenyl ring, a hallmark of several psychoactive substances within this category.

Pharmacology and effects

[edit]

As a dissociative drug, MDPCP exerts its effects primarily through antagonism of the NMDA receptor, resulting in altered sensory perceptions and dissociative states. The drug's subjective effects are reported to be similar to those of related arylcyclohexylamine derivatives.

Legal status

[edit]

Given its status as a novel psychoactive substance, MDPCP may be subject to varying degrees of legal control across different jurisdictions, often falling under generic legislation targeting arylcyclohexylamine derivatives or dissociative substances.

See also

[edit]
  • 3-F-PCP
  • 3-Methyl-PCPy
  • MXiPr
  • MDMAR
  • MDPM
  • MDPV
  • M-ALPHA

References

[edit]
  1. ^ Wallach JV (2014). Structure activity relationship (SAR) studies of arylcycloalkylamines as N-methyl-D-aspartate receptor antagonists (Ph.D. thesis). University of the Sciences in Philadelphia. 3690548.
  2. ^ Wallach J, Brandt SD (2018). "Phencyclidine-Based New Psychoactive Substances". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 261–303. doi:10.1007/164_2018_124. ISBN 978-3-030-10560-0. PMID 30105474.
  • v
  • t
  • e
Dissociatives
Arylcyclo‐
hexylamines
  • Ketamine-related: 2-Bromodeschloroketamine (2-BDCK; bromoketamine)
  • 2-Fluorodeschloroketamine (2-FDCK)
  • 2-FXPr
  • 3-Fluorodeschloroketamine (3-FDCK)
  • A-NK
  • Arketamine ((R)-ketamine)
  • Blixeprodil (GM-1020; (R)-4-FDCK)
  • Deoxymethoxetamine (DMXE)
  • Deschloroketamine (DXE, DCK)
  • Ethketamine (N-ethylnorketamine, NENK)
  • Esketamine ((S)-ketamine)
  • Fluorexetamine (3-FXE)
  • Hydroxetamine (HXE)
  • Ketamine (K)
  • Methoxetamine (MXE)
  • Methoxmetamine (MXM, MXME)
  • Methoxypropamine (MXPr)
  • Methoxyketamine
  • Methoxisopropamine (MXiPr)
  • Norketamine (NK)
  • SN-35210
  • TFMDCK
  • Tiletamine
  • Tilmetamine
  • XW10508
  • PCP-related: 2-Oxo-PCE
  • 3-Chloro-PCP
  • 3-Fluoro-PCP
  • 3-HO-PCP
  • 3-Me-PCE
  • 3-MeO-PCE
  • 3-MeO-PCMo
  • 3-MeO-PCP
  • 3-Methyl-PCP
  • 3-Methyl-PCPy
  • 4-Keto-PCP
  • 4-MeO-PCP
  • BDPC
  • Dieticyclidine (PCDE)
  • Eticyclidine (PCE)
  • MDPCP
  • PCPEP
  • PCPr
  • Phencyclidine (PCP)
  • Rolicyclidine (PCPy)
  • TCTHP
  • Tenocyclidine (TCP)
  • Others: Gacyclidine
Diarylethylamines
  • Diphenidine (1,2-DEP, DPD)
  • Ephenidine (NEDPA, EPE)
  • Fluorolintane (2-FPPP)
  • Methoxphenidine (MXP)
  • NPDPA (isopropylphenidine, isophenidine)
  • Remacemide
Morphinans
  • Dextrallorphan (DXA)
  • Dextromethorphan (DXM)
  • Dextrorphan (DXO)
  • Racemethorphan (methorphan)
  • Racemorphan (morphanol)
Inhalants
  • Aliphatic hydrocarbons
    • Butane
    • Gasoline
    • Kerosene
    • Propane
  • Ethers
    • Diethyl ether
    • Enflurane
    • Isoflurane
  • Haloalkanes
    • Chlorofluorocarbons
    • Chloroform
  • Nitrous oxide (N2O)
  • Xenon (Xe)
Others
  • 2-MDP (U-23807A)
  • 8A-PDHQ
  • Adamantanes (e.g., amantadine, memantine)
  • Alkyl nitrites/poppers (e.g., amyl nitrite)
  • Aptiganel (Cerestat; CNS-1102)
  • CNS-5161
  • Delucemine
  • Dexoxadrol
  • Dizocilpine (MK-801)
  • Etoxadrol
  • F-17475
  • Midafotel (CPPene)
  • NEFA
  • Neramexane
  • PD-137889
  • Perzinfotel
  • Selfotel (CGS-19755)
  • See also: Hallucinogens
  • Ionotropic glutamate receptor modulators
  • List of hallucinogens
  • v
  • t
  • e
Ionotropic glutamate receptor modulators
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
  • Agonists: Main site agonists: 5-Fluorowillardiine
  • Acromelic acid (acromelate)
  • AMPA
  • BOAA
  • Domoic acid
  • Glutamate
  • Ibotenic acid
  • Proline
  • Quisqualic acid
  • Willardiine; Positive allosteric modulators: Aniracetam
  • Cyclothiazide
  • CX-516
  • CX-546
  • CX-614
  • Farampator (CX-691, ORG-24448)
  • CX-717
  • CX-1739
  • CX-1942
  • Diazoxide
  • Hydrochlorothiazide (HCTZ)
  • IDRA-21
  • LY-392098
  • LY-395153
  • LY-404187
  • LY-451646
  • LY-503430
  • Mibampator (LY-451395)
  • Nooglutyl
  • ORG-26576
  • Oxiracetam
  • PEPA
  • Pesampator (BIIB-104, PF-04958242)
  • Piracetam
  • Pramiracetam
  • S-18986
  • Tulrampator (S-47445, CX-1632)
  • Antagonists: ACEA-1011
  • ATPO
  • Becampanel
  • Caroverine
  • CNQX
  • Dasolampanel
  • DNQX
  • Fanapanel (MPQX)
  • GAMS
  • Kaitocephalin
  • Kynurenic acid
  • Kynurenine
  • Licostinel (ACEA-1021)
  • NBQX
  • PNQX
  • Selurampanel
  • Tezampanel
  • Theanine
  • Topiramate
  • YM90K
  • Zonampanel; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
  • Cyclopropane
  • Enflurane
  • Ethanol (alcohol)
  • Evans blue
  • GYKI-52466
  • GYKI-53655
  • Halothane
  • Irampanel
  • Isoflurane
  • Perampanel
  • Pregnenolone sulfate
  • Sevoflurane
  • Talampanel; Unknown/unsorted antagonists: Minocycline
KARTooltip Kainate receptor
  • Agonists: Main site agonists: 5-Bromowillardiine
  • 5-Iodowillardiine
  • Acromelic acid (acromelate)
  • AMPA
  • ATPA
  • Domoic acid
  • Glutamate
  • Ibotenic acid
  • Kainic acid
  • LY-339434
  • Proline
  • Quisqualic acid
  • SYM-2081; Positive allosteric modulators: Cyclothiazide
  • Diazoxide
  • Enflurane
  • Halothane
  • Isoflurane
  • Antagonists: ACEA-1011
  • CNQX
  • Dasolampanel
  • DNQX
  • GAMS
  • Kaitocephalin
  • Kynurenic acid
  • Licostinel (ACEA-1021)
  • LY-382884
  • NBQX
  • NS102
  • Selurampanel
  • Tezampanel
  • Theanine
  • Topiramate
  • UBP-302; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
  • Enflurane
  • Ethanol (alcohol)
  • Evans blue
  • NS-3763
  • Pregnenolone sulfate
NMDARTooltip N-Methyl-D-aspartate receptor
  • Agonists: Main site agonists: AMAA
  • Aspartate
  • Glutamate
  • Homocysteic acid (L-HCA)
  • Homoquinolinic acid
  • Ibotenic acid
  • NMDA
  • Proline
  • Quinolinic acid
  • Tetrazolylglycine
  • Theanine; Glycine site agonists: β-Fluoro-D-alanine
  • ACBD
  • ACC (ACPC)
  • ACPD
  • AK-51
  • Apimostinel (NRX-1074)
  • B6B21
  • CCG
  • D-Alanine
  • D-Cycloserine
  • D-Serine
  • DHPG
  • Dimethylglycine
  • Glycine
  • HA-966
  • L-687,414
  • L-Alanine
  • L-Serine
  • Milacemide
  • Neboglamine (nebostinel)
  • Rapastinel (GLYX-13)
  • Sarcosine; Polyamine site agonists: Neomycin
  • Spermidine
  • Spermine; Other positive allosteric modulators: 24S-Hydroxycholesterol
  • DHEATooltip Dehydroepiandrosterone (prasterone)
  • DHEA sulfate (prasterone sulfate)
  • Epipregnanolone sulfate
  • Plazinemdor
  • Pregnenolone sulfate
  • SAGE-201
  • SAGE-301
  • SAGE-718
  • Antagonists: Competitive antagonists: AP5 (APV)
  • AP7
  • CGP-37849
  • CGP-39551
  • CGP-39653
  • CGP-40116
  • CGS-19755
  • CPP
  • Kaitocephalin
  • LY-233053
  • LY-235959
  • LY-274614
  • MDL-100453
  • Midafotel (d-CPPene)
  • NPC-12626
  • NPC-17742
  • PBPD
  • PEAQX
  • Perzinfotel
  • PPDA
  • SDZ-220581
  • Selfotel; Glycine site antagonists: 4-Cl-KYN (AV-101)
  • 5,7-DCKA
  • 7-CKA
  • ACC
  • ACEA-1011
  • ACEA-1328
  • Apimostinel (NRX-1074)
  • AV-101
  • Carisoprodol
  • CGP-39653
  • CNQX
  • D-Cycloserine
  • DNQX
  • Felbamate
  • Gavestinel
  • GV-196771
  • Harkoseride
  • Kynurenic acid
  • Kynurenine
  • L-689560
  • L-701324
  • Licostinel (ACEA-1021)
  • LU-73068
  • MDL-105519
  • Meprobamate
  • MRZ 2/576
  • PNQX
  • Rapastinel (GLYX-13)
  • ZD-9379; Polyamine site antagonists: Arcaine
  • Co 101676
  • Diaminopropane
  • Diethylenetriamine
  • Huperzine A
  • Putrescine; Uncompetitive pore blockers (mostly dizocilpine site): 2-MDP
  • 3-HO-PCP
  • 3-MeO-PCE
  • 3-MeO-PCMo
  • 3-MeO-PCP
  • 4-MeO-PCP
  • 8A-PDHQ
  • 18-MC
  • α-Endopsychosin
  • Alaproclate
  • Alazocine (SKF-10047)
  • Amantadine
  • Aptiganel
  • Argiotoxin-636
  • Arketamine
  • ARL-12495
  • ARL-15896-AR
  • ARL-16247
  • Budipine
  • CNS-5161
  • Coronaridine
  • Delucemine (NPS-1506)
  • Dexoxadrol
  • Dextrallorphan
  • Dextromethadone
  • Dextromethorphan
  • Dextrorphan
  • Dieticyclidine
  • Diphenidine
  • Dizocilpine
  • Ephenidine
  • Esketamine
  • Etoxadrol
  • Eticyclidine
  • F-17475
  • Fluorolintane
  • Gacyclidine
  • Ibogaine
  • Ibogamine
  • Indantadol
  • Ketamine
  • Ketobemidone
  • Lanicemine
  • Levomethadone
  • Levomethorphan
  • Levomilnacipran
  • Levorphanol
  • Loperamide
  • Memantine
  • Methadone
  • Methorphan
  • Methoxetamine
  • Methoxphenidine
  • Milnacipran
  • Morphanol
  • NEFA
  • Neramexane
  • Nitromemantine
  • Noribogaine
  • Norketamine
  • Orphenadrine
  • PCPr
  • PD-137889
  • Pethidine (meperidine)
  • Phencyclamine
  • Phencyclidine
  • Propoxyphene
  • Remacemide
  • Rhynchophylline
  • Rimantadine
  • Rolicyclidine
  • Sabeluzole
  • Tabernanthine
  • Tenocyclidine
  • Tiletamine
  • Tramadol; Ifenprodil (NR2B) site antagonists:
  • Besonprodil
  • Buphenine (nylidrin)
  • CO-101244 (PD-174494)
  • Eliprodil
  • Haloperidol
  • Isoxsuprine
  • Radiprodil (RGH-896)
  • Rislenemdaz (CERC-301, MK-0657)
  • Ro 8-4304
  • Ro 25-6981
  • Safaprodil
  • Traxoprodil (CP-101606); NR2A-selective antagonists: MPX-004
  • MPX-007
  • TCN-201
  • TCN-213; Cations: Hydrogen
  • Magnesium
  • Zinc; Alcohols/volatile anesthetics/related: Benzene
  • Butane
  • Chloroform
  • Cyclopropane
  • Desflurane
  • Diethyl ether
  • Enflurane
  • Ethanol (alcohol)
  • Halothane
  • Hexanol
  • Isoflurane
  • Methoxyflurane
  • Nitrous oxide
  • Octanol
  • Sevoflurane
  • Toluene
  • Trichloroethane
  • Trichloroethanol
  • Trichloroethylene
  • Urethane
  • Xenon
  • Xylene; Unknown/unsorted antagonists: ARR-15896
  • Bumetanide
  • Caroverine
  • Conantokin
  • D-αAA
  • Dexanabinol
  • Flufenamic acid
  • Flupirtine
  • FPL-12495
  • FR-115427
  • Furosemide
  • Hodgkinsine
  • Ipenoxazone (MLV-6976)
  • MDL-27266
  • Metaphit
  • Minocycline
  • MPEP
  • Niflumic acid
  • Pentamidine
  • Pentamidine isethionate
  • Piretanide
  • Psychotridine
  • Transcrocetin (saffron)
  • Unsorted: Allosteric modulators: AGN-241751
  • See also: Receptor/signaling modulators
  • Metabotropic glutamate receptor modulators
  • Glutamate metabolism/transport modulators
Retrieved from "https://teknopedia.ac.id/w/index.php?title=MDPCP&oldid=1330512990"
Categories:
  • Arylcyclohexylamines
  • Designer drugs
  • Benzodioxoles
  • Dissociative drugs
  • NMDA receptor antagonists
  • 1-Piperidinyl compounds
Hidden categories:
  • Articles with short description
  • Short description matches Wikidata
  • Short description is different from Wikidata
  • Articles without EBI source
  • Chemical pages without DrugBank identifier
  • Articles without KEGG source
  • Articles without UNII source
  • Drugs missing an ATC code
  • Drugs with no legal status
  • Articles containing unverified chemical infoboxes

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id